A PKM2 clinical trial has shown that inhibiting PKM2 significantly enhances the sensitivity of advanced bladder cancer cells to cisplatin, leading to increased apoptosis and reduced cell proliferation. The gene discussed is PKM; the disease is urinary bladder carcinoma.